Bank of New York Mellon Corp Has $5.82 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Bank of New York Mellon Corp trimmed its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 18.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 226,299 shares of the company's stock after selling 49,932 shares during the period. Bank of New York Mellon Corp owned 0.26% of IDEAYA Biosciences worth $5,816,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. R Squared Ltd acquired a new stake in shares of IDEAYA Biosciences during the fourth quarter valued at about $35,000. US Bancorp DE increased its stake in shares of IDEAYA Biosciences by 67.2% during the third quarter. US Bancorp DE now owns 1,714 shares of the company's stock worth $54,000 after buying an additional 689 shares during the period. KBC Group NV increased its stake in shares of IDEAYA Biosciences by 29.1% during the third quarter. KBC Group NV now owns 2,274 shares of the company's stock worth $72,000 after buying an additional 513 shares during the period. Quantbot Technologies LP purchased a new stake in shares of IDEAYA Biosciences during the third quarter worth approximately $83,000. Finally, Amalgamated Bank increased its stake in shares of IDEAYA Biosciences by 22.9% during the third quarter. Amalgamated Bank now owns 2,840 shares of the company's stock worth $90,000 after buying an additional 530 shares during the period. 98.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IDYA has been the subject of several research analyst reports. Wedbush reissued an "outperform" rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Stephens restated an "overweight" rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Royal Bank of Canada restated an "outperform" rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $53.58.

Remove Ads

IDEAYA Biosciences Trading Down 3.7 %

NASDAQ IDYA traded down $0.70 during trading hours on Tuesday, reaching $18.43. 153,939 shares of the company's stock were exchanged, compared to its average volume of 817,607. The stock has a market cap of $1.61 billion, a PE ratio of -5.57 and a beta of 0.76. IDEAYA Biosciences, Inc. has a one year low of $16.95 and a one year high of $46.40. The firm has a fifty day moving average of $21.82 and a 200-day moving average of $27.01.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The business had revenue of $7.00 million during the quarter, compared to analysts' expectations of $7.00 million. As a group, research analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.